Completed PHASE3 INTERVENTIONAL 2-arm NCT00689156

Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer (READ)

Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer

Sponsor: Dako

Conditions Breast Neoplasms

Interventions Epirubicin, cyclophosphamide and docetaxel docetaxel, cyclophosphamide

Updated 6 times since 2017 Last updated: Apr 3, 2018 Started: Jun 30, 2008 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00689156, this PHASE3 trial focuses on Breast Neoplasms and remains completed. Sponsored by Dako, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dako
Danish Breast Cancer Cooperative Group
Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning
Sanofi

Data source: Danish Breast Cancer Cooperative Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Copenhagen, Denmark , Esbjerg, Denmark , Herlev, Denmark , Herning, Denmark , Hillerød, Denmark , Næstved, Denmark , Odense, Denmark , Roskilde, Denmark and 3 more locations